SLS is trading 8.8% up at $13.47, extending a sharp multi-session rally as the market anticipates pivotal clinical results.
- The price action is driven by heightened buyout speculation and the imminent Phase 3 REGAL AML trial readout for its lead immunotherapy program.
- Strong institutional and retail interest continues to build as investors position for a binary outcome from the upcoming trial data.